Due to the special nature of medicines, returns and exchanges are not supported.

Final delivery from the nearest overseas warehous NEW

Imbruvica，伊布替尼（亿珂）

Ibrutinib (Imbruvica, trade name: Yike) is the world’s first BTK inhibitor approved for marketing. In November 2013, ibrutinib capsules (70 mg and 140 mg) were approved by the FDA for the treatment of mantle cell lymphoma.

Categories: Breast glands and blood, Oncology drugs, skin / lymph

Share:

Our offers

Saving your money for next purchases

Delivery – when you want and anywhere

A huge selection of best products

Health Classification

Let us work together to protect precious health

More